



Best Available Copy

**CERTIFICATION OF FACSIMILE TRANSMISSION**

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

**RENÉE Y. EDWARDS**

Type or print name of person signing certification

*Renée Y. Edwards*  
Signature

*March 21, 2005*  
Date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Cohen, *et al.*

Serial Number : 10/785,326

Filed: : February 24, 2004

For : METHODS OF PREVENTING  
BREAST CANCER

Docket No. : X-11057C

Group Art Unit:  
1614

Examiner:  
Delacroix Muirhei

**TERMINAL DISCLAIMER UNDER 37 C.F.R. 1.321**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**Identification of Person Making This Disclaimer**

I, Gilbert T. Voy, am employed by Eli Lilly and Company, and I am an attorney of record in the above-identified patent application. In that capacity, I am authorized to sign this disclaimer on behalf of Eli Lilly and Company.

**Identity of Assignee**

I hereby verify that the assignee owning all of the interest in this application is:

Eli Lilly and Company  
Lilly Corporate Center  
Indianapolis, Indiana 46285

**Recordal of Assignment in PTO**

The assignment was recorded on March 5, 1999, Reel 010383, Frame 0447.

**Extent of Interest**

The extent of Eli Lilly and Company's interest is in the whole of this invention.

03/25/2005 CNGUYEN 00000061 050840 10785326

02 FC:1814 130.00 DA

Best Available Copy

Serial No. 10/785,326

X11057C

**Disclaimer**

I hereby disclaim the terminal part of any patent granted on this application, which would extend beyond the expiration date of:

United States Patent No. 6,303,634 and hereby agree that any patent granted on this application shall be enforceable only for and during such period that the legal title to the patent shall be the same as the legal title to United States Patent No. 6,303,634.

I do not disclaim any terminal part of any patent granted on this application prior to the expiration date of the full statutory term of United States Patent No. 6,303,634 in the event that either of them later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to expiration of its full statutory term other than as presently shortened by any terminal disclaimer.

**Fee Payment**

Please charge the fee as designated by the attached Fee Transmittal, the fee set forth in 37 C.F.R. 1.20(d), and charge any additional fees which may be required by this or any other related paper, or credit any overpayment to Deposit Account No. 05-0840 in the name of Eli Lilly and Company. Two copies of this disclaimer are enclosed.

ELI LILLY AND COMPANY

By: 

Gilbert T. Voy  
Attorney for Applicant  
Registration No. 43,972  
Phone: 317-276-2966

Eli Lilly and Company  
Patent Division/GTV  
Lilly Corporate Center  
Indianapolis, Indiana 46285

March 21, 2005